vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.2倍（$188.3M vs $156.4M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs -21.9%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs -15.4%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
BCRX vs RILY — 直观对比
营收规模更大
RILY
是对方的1.2倍
$156.4M
营收增速更快
BCRX
高出29.3%
-21.9%
两年增速更快
BCRX
近两年复合增速
-15.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $188.3M |
| 净利润 | — | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 13.6% | 32.3% |
| 净利率 | — | 47.9% |
| 营收同比 | 7.5% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.00 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRILY
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $188.3M | ||
| Q3 25 | $159.4M | $215.3M | ||
| Q2 25 | $163.4M | $188.2M | ||
| Q1 25 | $145.5M | $197.2M | ||
| Q4 24 | $131.5M | $241.0M | ||
| Q3 24 | $117.1M | $225.5M | ||
| Q2 24 | $109.3M | $256.0M |
净利润BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $90.3M | ||
| Q3 25 | $12.9M | $91.1M | ||
| Q2 25 | $5.1M | $139.5M | ||
| Q1 25 | $32.0K | $-10.0M | ||
| Q4 24 | $-26.8M | $-5.6M | ||
| Q3 24 | $-14.0M | $-284.4M | ||
| Q2 24 | $-12.7M | $-433.6M |
毛利率BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 79.5% | ||
| Q3 25 | 98.6% | 83.7% | ||
| Q2 25 | 98.3% | 81.3% | ||
| Q1 25 | 96.9% | 81.4% | ||
| Q4 24 | 95.4% | 79.8% | ||
| Q3 24 | 97.3% | 82.1% | ||
| Q2 24 | 98.4% | 84.5% |
营业利润率BCRXRILY
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 32.3% | ||
| Q3 25 | 18.6% | 30.4% | ||
| Q2 25 | 18.2% | 5.7% | ||
| Q1 25 | 14.6% | -31.2% | ||
| Q4 24 | -3.4% | -69.2% | ||
| Q3 24 | 6.6% | -36.4% | ||
| Q2 24 | 8.0% | -90.8% |
净利率BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 47.9% | ||
| Q3 25 | 8.1% | 42.3% | ||
| Q2 25 | 3.1% | 74.1% | ||
| Q1 25 | 0.0% | -5.1% | ||
| Q4 24 | -20.4% | -2.3% | ||
| Q3 24 | -12.0% | -126.1% | ||
| Q2 24 | -11.6% | -169.4% |
每股收益（稀释后）BCRXRILY
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $2.78 | ||
| Q3 25 | $0.06 | $2.91 | ||
| Q2 25 | $0.02 | $4.50 | ||
| Q1 25 | $0.00 | $-0.39 | ||
| Q4 24 | $-0.13 | $-0.01 | ||
| Q3 24 | $-0.07 | $-9.39 | ||
| Q2 24 | $-0.06 | $-14.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | — | $-171.5M |
| 总资产 | $465.1M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRILY
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $226.6M | ||
| Q3 25 | $212.9M | $184.2M | ||
| Q2 25 | $260.0M | $267.4M | ||
| Q1 25 | $295.1M | $138.3M | ||
| Q4 24 | $320.9M | $146.9M | ||
| Q3 24 | $96.8M | $159.2M | ||
| Q2 24 | $78.4M | $236.9M |
总债务BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $-171.5M | ||
| Q3 25 | $-387.9M | $-260.5M | ||
| Q2 25 | $-421.6M | $-351.7M | ||
| Q1 25 | $-451.9M | $-496.8M | ||
| Q4 24 | $-475.9M | $-488.2M | ||
| Q3 24 | $-468.6M | $-497.6M | ||
| Q2 24 | $-475.6M | $-218.3M |
总资产BCRXRILY
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.7B | ||
| Q3 25 | $446.4M | $1.7B | ||
| Q2 25 | $457.2M | $1.5B | ||
| Q1 25 | $480.0M | $1.5B | ||
| Q4 24 | $490.4M | $1.8B | ||
| Q3 24 | $491.3M | $2.2B | ||
| Q2 24 | $472.4M | $3.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $26.2M | ||
| Q3 25 | $41.6M | $-60.6M | ||
| Q2 25 | $41.3M | $-25.6M | ||
| Q1 25 | $-27.5M | $184.0K | ||
| Q4 24 | $-5.2M | $-2.7M | ||
| Q3 24 | $8.2M | $19.5M | ||
| Q2 24 | $-1.4M | $111.5M |
自由现金流BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — |
自由现金流率BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — |
资本支出强度BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
现金转化率BCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 0.29× | ||
| Q3 25 | 3.23× | -0.66× | ||
| Q2 25 | 8.12× | -0.18× | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
